Nanoligent

Nanoligent is a private, preclinical-stage biotech founded in 2017 as a spin-off from the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. The company's core asset is its 'Precision Nanotherapy Platform,' which creates humanized, self-assembling protein nanoparticle conjugates for targeted drug delivery in cancer. Its lead program targets CXCR4 to halt tumor growth and metastasis and is in preclinical development. The company is backed by non-dilutive funding from Spanish and European public entities, positioning it to advance its first candidate toward clinical trials.

Precision Nanotherapy Platform: A protein engineering and nanobiotechnology platform that creates humanized, self-assembling protein nanoparticle conjugates for targeted drug delivery. Key features include nano-size for extended circulation, specific ligand targeting, humanized scaffolds to avoid immune response, protein-only composition for natural degradation, and drug conjugation for cell-killing efficacy.

Nanoligent competes in the targeted cancer therapy space, which includes large pharmaceutical companies and biotechs developing antibody-drug conjugates (ADCs), small molecule inhibitors, and other ligand-directed therapies. Its specific CXCR4 target is also being pursued by other modalities. Differentiation hinges on demonstrating superior targeting, safety, or efficacy with its unique protein-only nanoparticle approach.